CRBU [NASD]
Caribou Biosciences, Inc.
Index- P/E- EPS (ttm)-2.47 Insider Own0.90% Shs Outstand60.55M Perf Week2.90%
Market Cap346.59M Forward P/E- EPS next Y-1.82 Insider Trans1.36% Shs Float52.62M Perf Month-30.90%
Income-72.90M PEG- EPS next Q-0.36 Inst Own57.00% Short Float6.38% Perf Quarter-39.19%
Sales10.70M P/S32.39 EPS this Y-249.40% Inst Trans9.82% Short Ratio4.17 Perf Half Y-63.61%
Book/sh6.14 P/B0.93 EPS next Y-18.30% ROA-19.30% Target Price29.43 Perf Year-
Cash/sh5.80 P/C0.98 EPS next 5Y2.30% ROE-26.10% 52W Range4.89 - 32.65 Perf YTD-62.36%
Dividend- P/FCF- EPS past 5Y- ROI-16.90% 52W High-82.60% Beta-
Dividend %- Quick Ratio13.80 Sales past 5Y- Gross Margin- 52W Low16.16% ATR0.65
Employees97 Current Ratio13.80 Sales Q/Q68.80% Oper. Margin- RSI (14)36.78 Volatility7.94% 10.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-35.90% Profit Margin- Rel Volume0.75 Prev Close5.81
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume806.08K Price5.68
Recom1.40 SMA20-18.58% SMA50-25.28% SMA200-58.53% Volume607,714 Change-2.24%
Feb-18-22Initiated RBC Capital Mkts Outperform $22
Dec-01-21Initiated Oppenheimer Outperform $36
Nov-30-21Initiated H.C. Wainwright Buy $28
Nov-15-21Upgrade Citigroup Neutral → Buy $27
Aug-17-21Initiated SVB Leerink Outperform $32
Aug-17-21Initiated Citigroup Neutral $27
Aug-17-21Initiated BofA Securities Buy $30
Jun-13-22 02:41PM  
02:06PM  
Jun-10-22 03:00AM  
Jun-01-22 04:05PM  
May-16-22 04:05PM  
May-12-22 11:46AM  
10:00AM  
06:16AM  
May-11-22 04:00PM  
May-03-22 04:05PM  
May-02-22 04:30PM  
Apr-25-22 04:05PM  
Apr-21-22 09:33AM  
09:09AM  
Apr-08-22 01:07PM  
Mar-25-22 12:55PM  
Mar-21-22 04:02PM  
Mar-08-22 08:19PM  
Mar-07-22 04:11PM  
Mar-04-22 09:00AM  
Mar-01-22 05:44PM  
Feb-28-22 08:15PM  
Feb-22-22 09:17AM  
Feb-07-22 04:05PM  
Jan-21-22 05:37AM  
Jan-18-22 08:00AM  
Jan-04-22 04:05PM  
Dec-28-21 02:38AM  
Dec-11-21 10:06PM  
Dec-08-21 07:38PM  
07:38PM  
Nov-17-21 04:05PM  
Nov-09-21 04:05PM  
Nov-08-21 09:00AM  
Oct-23-21 08:41AM  
Oct-22-21 07:50AM  
Oct-20-21 04:00PM  
Oct-14-21 11:25AM  
Sep-29-21 04:05PM  
Sep-27-21 04:05PM  
Sep-02-21 04:05PM  
04:05PM  
Sep-01-21 08:00AM  
Aug-25-21 04:00PM  
Jul-27-21 04:05PM  
12:45PM  
Jul-22-21 09:09PM  
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kanner StevenChief Scientific OfficerMay 13Option Exercise1.8874,420140,081302,059May 17 08:51 PM
Haurwitz Rachel E.President and CEOMay 09Option Exercise2.9610,00029,60020,000May 10 07:32 PM
Fischesser RyanVP of Finance and ControllerMay 05Option Exercise3.402,2747,733115,518May 06 07:28 PM
Fischesser RyanVP of Finance and ControllerMar 15Option Exercise3.402,2747,733113,244Mar 17 07:14 PM
Kanner StevenChief Scientific OfficerMar 04Option Exercise2.9010,72031,036227,639Mar 07 07:58 PM
O'Byrne JasonChief Financial OfficerFeb 08Option Exercise4.1124,336100,02124,336Feb 08 07:27 PM
Haurwitz Rachel E.President and CEOJan 26Option Exercise2.9610,00029,6003,359,395Jan 27 04:41 PM
Fischesser RyanVP of Finance and ControllerJan 11Buy4.007,38729,553109,082Jan 12 04:35 PM
Fischesser RyanVP of Finance and ControllerDec 20Buy2.691,1363,056101,695Dec 21 05:23 PM
MCCLUNG BARBARA GChief Legal OfficerDec 07Buy2.696,12716,482348,971Dec 08 06:06 PM
MCCLUNG BARBARA GChief Legal OfficerOct 20Buy2.699,21924,799342,844Oct 21 06:12 PM
Kanner StevenChief Scientific OfficerOct 12Buy1.92114,860220,757215,031Oct 13 07:31 PM
Fischesser RyanVP of Finance and ControllerOct 11Buy2.691,7464,697100,559Oct 12 07:33 PM